S
SAB Biotherapeutics, Inc.
SABS · NASDAQ · Healthcare · 337M
Price · close
$3.78
+2.16% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
5.5×
Price / net assetsP/B
0.5×
Enterprise value / EBITDAEV/EBITDA
4.1×
Free cash flow yieldFCF yield
-62.6%
Return on equityROE
8.8%
Operating margin
—
Net debt / EBITDAbalance-sheet strength
-0.3×
Interest coverage
-203.4×
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.